- Home
- BQ vs CMND Comparison
BQ vs CMND Comparison
Compare BQ & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- CMND
- Stock Information
- Founded
- BQ 2008
- CMND 2017
- Country
- BQ China
- CMND Canada
- Employees
- BQ N/A
- CMND N/A
- Industry
- BQ Other Specialty Stores
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- CMND Health Care
- Exchange
- BQ Nasdaq
- CMND Nasdaq
- Market Cap
- BQ 4.8M
- CMND 5.5M
- IPO Year
- BQ 2020
- CMND N/A
- Fundamental
- Price
- BQ $0.48
- CMND $1.34
- Analyst Decision
- BQ
- CMND
- Analyst Count
- BQ 0
- CMND 0
- Target Price
- BQ N/A
- CMND N/A
- AVG Volume (30 Days)
- BQ 425.4K
- CMND 160.9K
- Earning Date
- BQ 12-18-2024
- CMND 11-26-2024
- Dividend Yield
- BQ N/A
- CMND N/A
- EPS Growth
- BQ N/A
- CMND N/A
- EPS
- BQ N/A
- CMND N/A
- Revenue
- BQ $98,241,396.00
- CMND N/A
- Revenue This Year
- BQ N/A
- CMND N/A
- Revenue Next Year
- BQ N/A
- CMND N/A
- P/E Ratio
- BQ N/A
- CMND N/A
- Revenue Growth
- BQ N/A
- CMND N/A
- 52 Week Low
- BQ $0.22
- CMND $0.92
- 52 Week High
- BQ $3.50
- CMND $6.80
- Technical
- Relative Strength Index (RSI)
- BQ 51.54
- CMND 44.72
- Support Level
- BQ $0.40
- CMND $1.33
- Resistance Level
- BQ $0.55
- CMND $1.58
- Average True Range (ATR)
- BQ 0.07
- CMND 0.11
- MACD
- BQ 0.00
- CMND -0.01
- Stochastic Oscillator
- BQ 59.70
- CMND 4.00
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump, and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.